Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMiravitlles Fernández, Marc
dc.contributor.authorRomán-Rodríguez, Miguel
dc.contributor.authorRibera, Xavier
dc.contributor.authorRitz, John
dc.contributor.authorIzquierdo Alonso, José Luis
dc.date.accessioned2022-08-10T09:32:24Z
dc.date.available2022-08-10T09:32:24Z
dc.date.issued2022-01-25
dc.identifier.citationMiravitlles M, Roman-Rodríguez M, Ribera X, Ritz J, Izquierdo JL. Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain. Int J Chron Obstruct Pulmon Dis. 2022 Jan 25;17:245–58.
dc.identifier.issn1178-2005
dc.identifier.urihttp://hdl.handle.net/11351/7979
dc.descriptionChronic obstructive pulmonary disease; Inhaled corticosteroids; Primary care
dc.description.abstractPurpose: Inhaled corticosteroids (ICS) are frequently used to treat chronic obstructive pulmonary disease (COPD) outside the current recommendations. Our aim was to describe ICS use in COPD patients and to identify factors associated with ICS use among COPD patients treated within primary care in Spain. Patients and Methods: This was a cross-sectional, non-interventional and multicenter study of patients with COPD treated in primary care. Patient characteristics and exacerbations were described in terms of ICS use among the overall cohort, and among those with spirometry confirmed COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] ratio < 70%). Multivariable logistic regression was used to identify factors associated with ICS use. Results: A total of 901 patients were included, of which 47.9% (n = 432) were treated with ICS. A total of 240 patients (26.6%) experienced moderate/severe exacerbations in the prior year, while 309 (34.3%) during the previous two years. History of asthma totaled 11.6% (n = 105). The most frequent phenotype was non-exacerbator (51.6%), and the proportion of patient with moderate or severe exacerbations was significantly higher among ICS treated patients compared to non-treated: 37.5% versus 16.6% during the previous year (p < 0.001), and 46.8% versus 22.8% during the previous 2-years (p < 0.001), respectively. Patient characteristics were similar among spirometry confirmed patients and the overall population. Factors significantly associated with ICS use were a history of asthma (OR = 4.39, 95% CI: 2.67– 7.26), the presence of moderate or severe exacerbations in the last year (OR = 2.52, 95% CI: 1.81– 3.49), followed by higher mMRC and higher CAT score. Conclusion: Nearly half of patients in primary care in Spain are treated with ICS, despite most of them being non-exacerbators. History of asthma, exacerbations, and worse dyspnea and CAT scores are associated with ICS use.
dc.language.isoeng
dc.publisherDove Medical Press
dc.relation.ispartofseriesInternational Journal of Chronic Obstructive Pulmonary Disease;17
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectPulmons - Malalties obstructives - Tractament
dc.subjectCorticosteroides - Ús terapèutic
dc.subject.meshPulmonary Disease, Chronic Obstructive
dc.subject.meshAdrenal Cortex Hormones
dc.subject.mesh/therapeutic use
dc.titleInhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2147/COPD.S342220
dc.subject.decsenfermedad pulmonar obstructiva crónica
dc.subject.decshormonas de la corteza suprarrenal
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://doi.org/10.2147/COPD.S342220
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Miravitlles M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain. [Roman-Rodríguez M] Centro de Salud Dra. Teresa Pique, Mallorca, Spain. Instituto de Investigación Sanitaria de las Islas Baleares (IdISBa), Mallorca, Spain. [Ribera X] Boehringer Ingelheim España, Barcelona, Spain. [Ritz J] Syneos Health - Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA. [Izquierdo JL] Department of Medicine and Medical Specialties, Universidad de Alcalá, Madrid, Spain. Pneumology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain
dc.identifier.pmid35115771
dc.identifier.wos000751813400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record